Verastem, Inc. (2VSA.F)

EUR 4.32

(-2.26%)

Total Debt Summary of Verastem, Inc.

  • Verastem, Inc.'s latest annual total debt in 2023 was 41.55 Million USD , up 53.55% from previous year.
  • Verastem, Inc.'s latest quarterly total debt in 2024 Q2 was 41.86 Million USD , down -1.0% from previous quarter.
  • Verastem, Inc. reported annual total debt of 27.06 Million USD in 2022, up 1095.45% from previous year.
  • Verastem, Inc. reported annual total debt of 2.26 Million USD in 2021, down -89.96% from previous year.
  • Verastem, Inc. reported quarterly total debt of 41.86 Million USD for 2024 Q2, down -1.0% from previous quarter.
  • Verastem, Inc. reported quarterly total debt of 42.93 Million USD for 2023 Q1, up 58.65% from previous quarter.

Annual Total Debt Chart of Verastem, Inc. (2023 - 2011)

Historical Annual Total Debt of Verastem, Inc. (2023 - 2011)

Year Total Debt Total Debt Growth
2023 41.55 Million USD 53.55%
2022 27.06 Million USD 1095.45%
2021 2.26 Million USD -89.96%
2020 22.54 Million USD -79.04%
2019 107.53 Million USD -10.73%
2018 120.45 Million USD 712.33%
2017 14.82 Million USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%

Peer Total Debt Comparison of Verastem, Inc.

Name Total Debt Total Debt Difference
BioNTech SE 219.1 Million EUR 81.033%
CureVac N.V. 41.85 Million EUR 0.72%
Biotest Aktiengesellschaft 689.8 Million EUR 93.976%
Biotest Aktiengesellschaft 689.8 Million EUR 93.976%
BRAIN Biotech AG 4.65 Million EUR -791.973%
Formycon AG 29.48 Million EUR -40.938%
Heidelberg Pharma AG 5.83 Million EUR -612.645%
Medigene AG 2.95 Million EUR -1308.712%